Renate Strehlau to Ritonavir
This is a "connection" page, showing publications Renate Strehlau has written about Ritonavir.
Connection Strength
1,906
-
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
Score: 0,474
-
Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz. Bone. 2020 09; 138:115500.
Score: 0,168
-
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
Score: 0,166
-
Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
Score: 0,148
-
Reply to Van de Wijer et al. Clin Infect Dis. 2018 03 19; 66(7):1151-1152.
Score: 0,143
-
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.
Score: 0,137
-
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014 Feb 12; 14:39.
Score: 0,108
-
Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013 Jun; 162(6):1138-45, 1145.e1-2.
Score: 0,100
-
Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
Score: 0,097
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,095
-
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
Score: 0,083
-
Persistently lower bone mass and bone turnover among South African children living with well controlled HIV. AIDS. 2021 11 01; 35(13):2137-2147.
Score: 0,046
-
Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018 Apr 05; 13(1):40.
Score: 0,036
-
Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016 10 23; 30(16):2459-2467.
Score: 0,033
-
Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2013 May; 32(5):489-94.
Score: 0,026
-
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
Score: 0,025
-
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
Score: 0,022